Skip to main content
. Author manuscript; available in PMC: 2022 Sep 6.
Published in final edited form as: Nat Rev Clin Oncol. 2021 Apr 28;18(9):547–557. doi: 10.1038/s41571-021-00501-4

Table 2 |.

Ongoing phase III studies of neoadjuvant therapy in non-metastatic non-small cell lung cancer.

Neoadjuvant Control n Adjuvant End points Biomarker Refs
Platinum doublet + durvalumab Platinum doublet + placebo 800 Durvalumab versus placebo MPR
EFS		 PD-L1 positivity NCT03800134 (REF.139)
Platinum doublet + atezolizumab Platinum doublet + placebo 450 Atezolizumab versus placebo EFS
MPR		 PD-L1 positivity NCT03456063 (REF.140)
Cisplatin doublet + pembrolizumab Cisplatin doublet + placebo 786 Pembrolizumab versus placebo EFS
OS		 PD-L1 positivity NCT03425643 (REF.141)
Ipilimumab + nivolumab or chemotherapy + nivolumab Chemotherapy 350 None EFS
pCR		 PD-L1 positivity NCT02998528 (REF.142)
Osimertinib or osimertinib + chemotherapy Chemotherapy 351 Not specified MPR EGFR mutation NCT04351555 (REF.108)

EFS, event-free survival; MPR, major pathologic response; pCR, pathologic complete response; OS, overall survival.